In partnership with

  • Conferences
  • Disease Areas
  • News
  • Articles
  • Contact
    • twitter
    Highlights from

    ASH 2019

    61st Annual Meeting & Exposition of the American Society of Hematology

    Orlando, Florida (USA) 7 - 10 December 2019

    Articles

    Letter from the editor

    Letter from the editor

    Late-Breaking Abstracts

    Likely new standard of care: blinatumomab for children with relapsed B-ALL

    Pivotal phase 3 trial in cold agglutinin disease: sutimlimab can stop haemolysis

    Oral azacitidine improves overall survival in patients with AML in remission

    BCL11A as a novel target in gene therapy for sickle cell disease

    Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM

    Long-term data of ropeginterferon alpha-2b in polycythaemia vera

    Anti-CD70 is safe with hypomethylating agents in AML

    MRD assessment to guide pre-emptive treatment decisions

    Luspatercept effective for myelofibrosis-associated anaemia

    Arsenic, ATRA, and ascorbic acid in acute promyelocytic leukaemia maintenance

    Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT

    Sickle Cell Disease

    Arginine supplements help against sickle cell disease pain

    Abatacept prevents graft-versus-host disease in sickle cell patients after alloSCT

    Plenary Scientific Session

    HOVON-96: Better outcomes with cyclophosphamide after transplantation

    Erythroferrone and skeletal changes associated with thalassaemia

    Gene editing in congenital neutropenia

    Experimental model for limitations of haematopoietic stem cells propagation

    Mosunetuzumab: complete remissions in non-Hodgkin lymphoma

    Inclusive Medicine

    Socioeconomic disparities and survival in paediatric AML

    Oral selinexor/pomalidomide/dexamethasone shows activity in heavily pre-treated multiple myeloma

    CAR T-cell therapy successful in older non-Hodgkin’s lymphoma patients

    Mild renal impairment in African Americans does not affect OS in AML

    ALCYONE: New overall survival results for myeloma

    Venous Thromboembolism

    Rivaroxaban is safe and effective for paediatric venous thromboembolism

    Aspirin plus DOAC is not better than a DOAC alone

    20-Year follow-up of imatinib in chronic myeloid leukaemia after failure with interferon

    CAR T and Beyond

    BCMA-targeted CAR T therapy yields 100% response in relapsed/refractory MM

    Anti-BCMA/anti-CD38 in refractory multiple myeloma

    Off-the-shelf natural killer cells

    Top image: @ iStockPhoto: ustas7777777

    The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.

    BACK TO TOP